Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06003218 | Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation | completed | N/A | 88 | Peking University First HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04316182 | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)(ACTION) | completed | Phase 2 | 24 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899763 | Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy(1003rcr2022_72) | completed | — | 6 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02052778 | A Study of TAS-120 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 407 | Taiho Oncology, Inc.INDUSTRY | 13 | Mar 27, 2025 | clinicaltrials |
| NCT06416683 | Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)(ABCHCaen) | completed | — | 109 | University Hospital, CaenOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04137289 | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 110 | Boehringer IngelheimINDUSTRY | 8 | Mar 25, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06503250 | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | completed | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06888401 | Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Care Center of Nepal | completed | — | 597 | Kathmandu University School of Medical SciencesOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04484636 | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)(PLATON) | completed | N/A | 400 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06223061 | Global Evaluation of Cholecystectomy Knowledge and Outcomes(GECKO) | completed | — | 53,708 | University of EdinburghOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT03397654 | Study of Pembrolizumab Following TACE in Primary Liver Carcinoma(PETAL) | completed | Phase 1 / Phase 2 | 26 | Imperial College LondonOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT05233098 | TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | completed | — | 6 | Boston Scientific CorporationINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT04297280 | TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04948697 | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | completed | Phase 2 | 94 | BeiGeneINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT05010668 | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 28 | Fudan UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04022746 | An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer | completed | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06037343 | Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI | completed | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04306367 | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | completed | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05236699 | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC(CCGLC-005) | completed | Phase 2 | 23 | Tongji HospitalOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05162352 | Donafenib Plus Sintilimab for Advanced HCC | completed | Phase 2 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03439891 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | completed | Phase 2 | 16 | Robin Kate KelleyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04361331 | Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma | completed | Phase 2 | 61 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT01804166 | A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) | completed | Phase 4 | 1 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02421185 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 53 | Janssen Research & Development, LLCINDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT04511455 | Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment | completed | Phase 2 | 22 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04522908 | Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function | completed | Phase 2 | 40 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06720675 | Ex-vivo Hypotermic Perfusion in Patients With Hepatocellular Carcinoma to Reduce the Incidence of Tumor Recurrence | completed | — | 237 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT05431621 | Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers | completed | — | 2,430 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT05848947 | SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA(MAApping) | completed | Phase 4 | 5 | Sirtex MedicalINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06799468 | Validation of the TRAIN-AI for the Risk of HCC Recurrence After Liver Transplantation(TRAIN-AI) | completed | — | 1,769 | European Hepatocellular Cancer Liver Transplant GroupOTHER | 0 | Jan 29, 2025 | clinicaltrials |
| NCT05462314 | Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies | completed | — | 24 | ViomeINDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT04767906 | Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors(CaPture) | completed | Phase 2 | 16 | University of LeipzigOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06776185 | Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma | completed | — | 3,000 | Chen XiaopingOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT04272619 | Liver Cancer Community Education | completed | N/A | 67 | Fox Chase Cancer CenterOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06760494 | Microvascular Invasion Artificial Intelligence Prediction Via Contrast-enhanced Ultrasound With Explainability(MAPUSE) | completed | — | 250 | Chinese PLA General HospitalOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03756051 | Harms of Hepatocellular Carcinoma Surveillance | completed | — | 2,871 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2025source: clinicaltrials